Jacob M. Chacko, M.D.

Dr. Jacob M. Chacko, M.D. has played a pivotal role at ORIC Pharmaceuticals since joining the company in May 2018 as Chief Executive Officer, a position that reflects his extensive expertise in the biotechnology and healthcare sectors.

He built a formidable academic profile by earning advanced degrees from top-tier institutions, including a B.A. in Biology and a B.S. in Gerontology from the University of Southern California, an M.D. from the University of California, Los Angeles, an M.B.A. from Harvard Business School, and an M.Sc. from Oxford University.

Prior to his tenure at ORIC, he held significant roles such as Chief Financial Officer at Ignyta, Inc., where he contributed during its acquisition by Roche, and served as Vice President at TPG Capital, alongside providing consultancy services at McKinsey & Company. His diverse experience has underpinned ORIC's strategic initiatives, including advancing clinical programs and securing substantial financing to extend the company's growth trajectory.

No information available on performance compensation for 2023.